US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
ET

ETON

Stock Eton Pharmaceuticals Inc
$57.08

Nasdaq Global Market · Healthcare · US

Sharia status
COMPLIANT
Per our secondary compliance provider · assessed 2026-08-25
HTR non-permissible income 0.35%

Methodology breakdown computing — it will appear here on its own.

🕌Open research, not a fatwa — verify with your own scholar.
Trade setup SEPARATE FROM SHARIAH
🟢 STRONG BUY SETUP
Strong confluence across multiple layers — outperforming the market by 45.7%, RSI in healthy zone, Wall Street...
48
of 100
Setup confidence — system conviction, not win probabilityD
Trade plan PM_HIGH · SCALP
Entry
$61.49
Stop
$60.16
Target
$64.16
Risk : Reward 2.0R
Why this signal?
Structure1 of 5 timeframes bullish · 78.3% aligned
VWAPPrice below VWAP ($58.37)
VolumeRelative volume 2.3× the 20-day average
Momentum10-day rate of change -6.2%
Overall readSTRONG BUY SETUP

Eton Pharmaceuticals Inc (ETON) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-25). See the full ratio breakdown and business-activity screen below for the reasoning.

Market & analysts
Wall Street consensus
BUY
10 analysts
Institutional own.
70.3%
of shares
Momentum (10d)
-6.2%
rate of change
SMC grade
D · 48
78.3% aligned
COMPLIANT
Sharia compliance
0.35%
Non-permissible income — HTR, from filings (2025-12-31)
D · 48
SMC grade — 78.3% timeframe alignment
-6.2%
Rate of change (10d)
BUY
Wall Street consensus (10)
70.3%
Institutional ownership

🕌 In-house Compliance Research

Computing the full ratio and business-activity breakdown for ETON — this runs off the critical path so the page paints first. It will appear here on its own.

64.4351.9139.3926.8714.352025-09-122026-03-132026-09-11

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
55.20
S2
56.41
S1
57.14
PIVOT
58.35
R1
59.08
R2
60.29
R3
61.02

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

7-day expected range
48.76 72.10
±19.31% from 60.43, made 2026-09-02 · resolves 2026-09-09
STRONG BUY
from 19 indicators
Not enough resolved predictions yet — 0 of 10 needed before we publish an accuracy figure. 22521 forecast(s) are currently open and will be scored automatically when their horizon expires.

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

Technical Summary

BUY
19 indicators
OscillatorsNEUTRAL
3 buy · 1 neutral · 3 sell
Moving averagesSTRONG BUY
8 buy · 0 neutral · 4 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)52.60NEUTRAL
Stochastic %K (14)9.45BUY
CCI (20)-117.46BUY
Williams %R (14)-90.55BUY
MACD (12,26,9)-1.17SELL
ROC (10)-8.92SELL
Momentum (10)-5.59SELL
EMA (10)58.95SELL
SMA (10)59.41SELL
EMA (20)57.68SELL
SMA (20)60.79SELL
EMA (30)55.37BUY
SMA (30)55.27BUY
EMA (50)50.87BUY
SMA (50)49.50BUY
EMA (100)42.78BUY
SMA (100)39.95BUY
EMA (200)32.98BUY
SMA (200)29.11BUY

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

About Eton Pharmaceuticals Inc

Healthcare · Drug Manufacturers - Specialty & Generic

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

etonpharma.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Latest Signal — 2026-09-01

PM_HIGH
Type · SCALP
61.49
Entry
60.16
Stop
64.16
Target
LOSS
Outcome
Verdict

🟢 STRONG BUY SETUP

Strong confluence across multiple layers — outperforming the market by 45.7%, RSI in healthy zone, Wall Street broadly bullish. High conviction entry. Use `!plan ETON [entry] [stop] [target]` to size the position properly.

Scores: 4 bullish / 1 bearish

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

TimeframeBiasBars
📅 Daily BEARISH 62
⏰ 4H BEARISH 40
🕐 1H RANGING 98
⏱ 15-Min BEARISH 130
⏲ 5-Min BULLISH 234

Momentum & Volume

2.74
MACD (no fresh cross)

Peer Movement

Peer movement computing — it will appear here on its own.

Insider Activity (90d)

CLUSTER SELL   0 buys · 16 sells

Recent: Opaleye Management Inc. sold 2680000 sh @ $38.37 (2026-07-07); Opaleye Management Inc. sold 2700000 sh @ $38.00 (2026-07-06); Opaleye Management Inc. sold 2710000 sh @ $37.39 (2026-07-02)

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

NEUTRAL   report date 2026-09-08 · Asset managers net 912361 (-21819)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.

Tell us what's working, what's confusing, or what you want to see next — read by a real person, not a form that goes nowhere.